Protagonist Therapeutics Inc diskutieren
Protagonist Therapeutics Inc
WKN: A2AP32 / Symbol: PTGX / Name: Protagonist / Aktie / Micro Cap /
86,50 €
2,37 %
Protagonist Therapeutics (NASDAQ:PTGX) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $80.00 price target on the stock.
Ratings data for PTGX provided by MarketBeat
Protagonist Therapeutics (NASDAQ:PTGX) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $80.00 price target on the stock.
Ratings data for PTGX provided by MarketBeat
Protagonist Therapeutics (NASDAQ:PTGX) had its "outperform" rating reaffirmed by analysts at BMO Capital Markets.
Ratings data for PTGX provided by MarketBeat
Protagonist Therapeutics (NASDAQ:PTGX) had its price target raised by analysts at Wedbush from $70.00 to $86.00. They now have an "outperform" rating on the stock.
Ratings data for PTGX provided by MarketBeat
Protagonist Therapeutics (NASDAQ:PTGX) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $82.00 price target on the stock.
Ratings data for PTGX provided by MarketBeat
Protagonist Therapeutics (NASDAQ:PTGX) was given a new $88.00 price target on by analysts at Truist Financial Corporation. They now have a "buy" rating on the stock.
Ratings data for PTGX provided by MarketBeat
Protagonist Therapeutics (NASDAQ:PTGX) had its price target raised by analysts at Barclays PLC from $72.00 to $88.00. They now have an "overweight" rating on the stock.
Ratings data for PTGX provided by MarketBeat
Protagonist Therapeutics (NASDAQ:PTGX) had its price target raised by analysts at JPMorgan Chase & Co. from $68.00 to $81.00. They now have an "overweight" rating on the stock.
Ratings data for PTGX provided by MarketBeat
Protagonist Therapeutics (NASDAQ:PTGX) had its price target raised by analysts at Citigroup Inc. from $96.00 to $98.00. They now have a "buy" rating on the stock.
Ratings data for PTGX provided by MarketBeat
Protagonist Therapeutics (NASDAQ:PTGX) had its price target raised by analysts at Jefferies Financial Group Inc. from $95.00 to $118.00. They now have a "buy" rating on the stock.
Ratings data for PTGX provided by MarketBeat
Protagonist Therapeutics (PTGX) had its price target raised by Barclays PLC from $108.00 to $113.00. They now have an "overweight" rating on the stock.
Ratings data for PTGX provided by MarketBeat
Protagonist Therapeutics (PTGX) had its price target raised by TD Cowen from $90.00 to $100.00. They now have a "buy" rating on the stock.
Ratings data for PTGX provided by MarketBeat
Protagonist Therapeutics (PTGX) had its "buy" rating reaffirmed by Johnson Rice.
Ratings data for PTGX provided by MarketBeat
Protagonist Therapeutics (PTGX) had its "buy" rating reaffirmed by Jefferies Financial Group Inc..
Ratings data for PTGX provided by MarketBeat
Neueste Beiträge
Truist_Financial_Co_ in Altimmune diskutieren